Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow relaxing and invigorating, because that oh-so predictable routine of Zoom meetings, Skype calls, and deadlines has predictably returned. To cope, yes, we are brewing cups of stimulation. Our choice today is maple bourbon. Feel free to join us. Remember, no prescription is required. Meanwhile, here is the daily menu of tidbits. We hope your day is productive and satisfying. Meanwhile, stay in touch and stay safe — wear a mask. …

President-elect Joe Biden picked California Attorney General Xavier Becerra to be his health secretary, putting a defender of the Affordable Care Act in a leading role to oversee his administration’s coronavirus response, the Associated Press writes. Separately, Biden picked a Harvard infectious disease expert, Rochelle Walensky, to head the Centers for Disease Control and Prevention. And he announced a new role for Dr. Anthony Fauci, the government’s top infectious disease expert.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Interesting ending line – “…as regulators continue to struggle with the difficulties posed by the Covid-19 pandemic, which has caused the U.S. Food and Drug Administration to delay some approvals.”
    As I recall, FDA was insisting things were moving along on schedule … but that may have been some time ago.

Comments are closed.